ArticleScientific reports2017
Susceptibility profiles of Nocardia spp. to antimicrobial and antituberculotic agents detected by a microplate Alamar Blue assay.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- The species distribution and antimicrobial resistance profiles of Nocardia species in China: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2023Pooled it
- Nocardiosis: A Neglected Disease.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2020Pooled it
- Case Report of a Solitary Brain Abscess due toCase reports in infectious diseases · 2026Article
- Research progress on clinical challenges and prevention strategies of drug-resistantFrontiers in public health · 2026Review
- Phylogenetic and Genomic Feature Analysis of CutaneousInfection and drug resistance · 2026Article
- It never rains but pours: disseminated nocardiosis in a renal transplant patient from Nigeria - a case report.BMC infectious diseases · 2025Article
- Article
- Antibiotic Susceptibility ofChina CDC weekly · 2025Article
- Linezolid and Meropenem for Nocardia otitidiscaviarum Actinomycetoma, India.Emerging infectious diseases · 2025Article
- Clinical Features of Pulmonary Nocardiosis and Diagnostic Value of Metagenomic Next-Generation Sequencing: A Retrospective Study.Pathogens (Basel, Switzerland) · 2025Article
- Nocardiosis in a Patient with Nephrotic Syndrome Treated with Glucocorticoids and Tacrolimus.Internal medicine (Tokyo, Japan) · 2025Article
- Article
- Primary Cutaneous Nocardiosis (Lymphangitic Type) in an Immunocompetent Patient: A Case Report.Microorganisms · 2025Article
- The Impact of Tetracycline on the Soil Microbiome and the Rhizosphere of Lettuce (International journal of molecular sciences · 2025Article
- Genomic and phenotypic characterization of antimicrobial resistance in clinicalFrontiers in cellular and infection microbiology · 2025Article
- Multiple skin abscesses due to Nocardia neocaledoniensis: a case report and literature review.BMC infectious diseases · 2024Review
- A modular toolkit for environmentalApplied and environmental microbiology · 2024Article
- Importance of clinico-pathologic correlation in rare, chronic infectious diseases: Actinomycetoma misdiagnosed as botryomycosis-A case report.Clinical case reports · 2024Article
- Biochemical and structural characterization of a class A β-lactamase from Nocardia cyriacigeorgica.Acta crystallographica. Section F, Structural biology communications · 2024Article
- Comparison of Clinical Characteristics and Treatment Outcome Between Localized and Disseminated Nocardiosis in a Tertiary Hospital in China.Infection and drug resistance · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Nocardia species are ubiquitous in natural environments and can cause nocardiosis. Trimethoprim-sulfamethoxazole has long been the monotherapy treatment of choice, but resistance to this treatment has recently emerged. In this study, we used microplate Alamar Blue assays to determine the antimicrobial susceptibility patterns of 65 standard Nocardia isolates, including 28 type strains and 20 clinical Nocardia isolates, to 32 antimicrobial agents, including 13 little studied drugs. Susceptibility to the most commonly used drug, trimethoprim-sulfamethoxazole, was observed in 98% of the isolates. Linezolid, meropenem, and amikacin were also highly effective, with 98%, 95%, and 90% susceptibility, respectively, among the isolates. The isolates showed a high percentage of resistance or nonsusceptibility to isoniazid, rifampicin, and ethambutol. For the remaining antimicrobials, resistance was species-specific among isolates and was observed in traditional drug pattern types. In addition, the antimicrobial susceptibility profiles of a variety of rarely encountered standard Nocardia species are reported, as are the results for rarely reported clinical antibiotics. We also provide a timely update of antimicrobial susceptibility patterns that includes three new drug pattern types. The data from this study provide information on antimicrobial activity against specific Nocardia species and yield important clues for the optimization of species-specific Nocardia therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.